Julian Adams

Julian Adams

Auto-generated profile, based on publicly available information

Julian Adams

Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2003 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
JAJ Adams
J Adams

1 February 2002 in The Oncologist
Verified
Journal Article
Closed access
PDF file
JAJulian Adams
Julian Adams
Over the last decade, the critical role of the proteasome in cell-cycle regulation has become increasingly apparent. The proteasome, a multicatalytic protease present in all eukaryotic cells, is the primary component of the protein degradation pathway of the cell. By degrading regulatory proteins (or their inhibitors), the proteasome serves as a central conduit for many cellular regulatory signals and, thus, is a novel target for therapeutic drugs. PS-341 is a small molecule that is a potent and selective inhibitor of the proteasome. In vitro and mouse xenograft studies of PS-341 have shown antitumor activity in a variety of tumor types, including myeloma, chronic lymphocytic leukemia, prostate cancer, pancreatic cancer, and colon cancer, among others. Although PS-341 rapidly leaves the vascular compartment, a novel pharmacodynamic assay has shown that inhibition of proteasome—the biologic target—is dose dependent and reversible. These studies provided the rationale for a twice-weekly dosing schedule employed in ongoing clinical studies. Phase I trials in a variety of tumor types have shown PS-341 to be well tolerated, and phase II trials in several hematologic malignancies and solid tumor types are now in progress. Efficacy and safety data from the most advanced of these, a phase II multicenter trial in myeloma, will be available in early 2002.

1 April 2003 in Drug Discovery Today
Verified
Journal Article
Closed access
JAJ Adams
J Adams

1 April 2002 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
JAJulian Adams
Julian Adams

1 September 2002
Verified
Journal Article
Closed access
RLRichard LeBlanc
Richard LeBlanc
LCLaurence P Catley
Laurence P Catley
THTeru Hideshima
Teru Hideshima
SLSuzanne Lentzsch
Suzanne Lentzsch
CMConstantine Mitsiades
Constantine Mitsiades
KAKenneth C Anderson
Kenneth C Anderson

1 November 2002 in Current Opinion in Oncology
Verified
Journal Article
Closed access
JAJulian Adams
Julian Adams
The targeted degradation of key regulatory proteins is an essential element of cell cycle control. The proteasome plays a central role in the degradation of such proteins and has therefore become an important therapeutic target for diseases involving cell proliferation, notably cancer. This review summarizes numerous studies demonstrating that proteasome inhibition induces apoptosis and sensitizes cancer cells to traditional tumoricidal agents both in vitro and in vivo. The potent and selective proteasome inhibitor, PS-341, is particularly promising from a therapeutic perspective, and it is the only such inhibitor that has progressed to clinical trials. Preliminary data indicate that the drug is well tolerated by patients with cancer, and further trials are underway to assess the safety and efficacy of proteasome inhibition in hematologic and solid tumors, both as a monotherapy and in combination with other chemotherapeutics.